Curated News
By: NewsRamp Editorial Staff
May 19, 2026

Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference

Original Source

TLDR

  • Oragenics presents at Sidoti conference, offering investors early access to a potential first-in-class concussion treatment.
  • Oragenics uses proprietary intranasal delivery to target the brain, advancing ONP-002 for concussion and other neurological conditions.
  • Oragenics develops therapies for concussion, Alzheimer's, and PTSD, aiming to improve neurological care and quality of life.
  • Oragenics brain-targeting nasal spray could revolutionize treatment for concussion and mild traumatic brain injury.

Impact - Why it Matters

This news matters because it signals Oragenics' continued engagement with the investment community as it advances ONP-002, a potential breakthrough treatment for concussion and mild traumatic brain injury. With no FDA-approved treatments for concussion, Oragenics' intranasal delivery platform could revolutionize neurological care. For investors, this presents an opportunity to learn about a clinical-stage company targeting a large, underserved market. The Sidoti conference allows direct interaction with management, potentially influencing investment decisions.

Summary

Oragenics (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on neurological therapeutics, has announced its participation in the Sidoti Micro-Cap Virtual Investor Conference scheduled for May 20-21, 2026. The company will present on May 21 at 3:15 p.m. ET and will hold one-on-one meetings with investors throughout the conference. This event provides a platform for Oragenics to showcase its innovative pipeline and engage with the investment community.

Oragenics is developing brain-targeted therapeutics using its proprietary intranasal delivery technology. Its lead candidate, ONP-002, is a potential first-in-class treatment for concussion and mild traumatic brain injury. The company is preparing to commence clinical trials in Australia, with U.S. Phase 2b trials planned thereafter. The intranasal platform holds promise for other neurological conditions such as Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders, addressing significant unmet medical needs. Investors can find the latest news and updates relating to OGEN in the company’s newsroom.

InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, distributed this press release. InvestorWire provides wire-grade press release syndication and a range of corporate communications solutions to help companies reach investors, media, and the public. The platform offers access to a vast network, editorial syndication to 5,000+ outlets, and social media distribution. For more information, visit InvestorWire.com.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference

blockchain registration record for this content.